Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Teva Pharmaceutical Industries Ltd. Stories

2014-03-30 23:21:43

Texas Medicaid fraud attorney J. Mark Brewer says he hopes $27 million payments by Teva Pharmaceutical Industries Ltd. to resolve allegations of illegal payments to a doctor to prescribe certain drugs sends a strong message to other drug companies. Houston, TX (PRWEB) March 30, 2014 Teva Pharmaceutical Industries Ltd. recently agreed to pay the federal government and the State of Illinois $27.6 million to resolve allegations of illegally paying a doctor to prescribe certain dangerous...

2013-11-07 16:30:43

Conference call to be held on Thursday, November 7 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 7, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2013 financial results and will address frequently asked questions from investors during the quarterly conference call. Questions, including recent inquiries regarding the clinical development program and prostate cancer market landscape, were submitted via the...

2013-09-24 12:28:57

NORTH WALES, Pa., Sept. 24, 2013 /PRNewswire/ -- Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette(TM) (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets are now available via prescription in the U.S. for the prevention of pregnancy. Quartette(TM) represents the only extended-regimen oral contraceptive approved by the U.S. Food and Drug Administration (FDA) with an ascending dose of...

2013-08-12 08:30:11

JERUSALEM and ALLEGAN, Mich., Aug. 12, 2013 /PRNewswire/ -- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Perrigo Company (NYSE: PRGO;TASE) today announced the launch of the generic equivalent to Temodar® (temozolomide). Teva will manufacture, market and distribute the product in the U.S. and both companies will equally share in the cost and profitability of the product in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity....

2013-05-15 08:29:27

ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights. Operational Highlights Emphasis on C. difficile (C. diff) Infection Prevention (SYN-004) In the U.S. each year, 24 million patients are administered IV antibiotics([1]) which may be excreted...

2013-05-08 08:30:57

Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder NORTH WALES, Pa. and MOUNTAIN VIEW, Calif., May 8, 2013 /PRNewswire/ -- Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE...

2013-04-04 16:23:46

-- Patent Expands Company's Patent Portfolio to Include Combination with Number One Selling Multiple Sclerosis Drug -- ROCKVILLE, Md., April 4, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,372,826 entitled, Estriol Therapy for Multiple Sclerosis and Other Autoimmune...

2013-03-13 08:27:54

Walker's Charity, Band Against MS Teams Up with Teva Pharmaceuticals to Launch Public Service Announcement Campaign and Raise Money for MS Research FRAZER, Pa., March 13, 2013 /PRNewswire/ -- Country music singer Clay Walker today announced the launch of "Stick With It!," a national public service announcement campaign to educate relapsing-remitting multiple sclerosis (RRMS) patients about the importance of remaining adherent to a disease management routine for the long-term. Teva...

2013-03-11 12:24:22

CHICAGO, March 11, 2013 /PRNewswire/ -- Zacks Equity Research highlights Winnebago Industries, Inc. (NYSE:WGO) as the Bull of the Day and Gold Fields Limited (NYSE:GFI) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Biogen (Nasdaq:BIIB) and Novartis (NYSE:NVS). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678. Here is a...